ShangPharma Corporation to Announce Second Quarter 2011 Financial Results on August 22, 2011
SHANGHAI, July 27, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2011 on August 22, 2011. Management will host a conference call to discuss the results at 8:00 am New York Time on August 22, 2011 (8:00 pm Beijing time on August 22, 2011).
Conference Call
Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, Mr. William Dai, Chief Financial Officer, and Ms. Lan Xie, Vice President of Finance and Operations, will discuss the results and take questions following the prepared remarks.
The dial-in details for the live conference call are as follows:
- U.S. Toll Free Number: |
1.800.901.5231 |
|
- International dial-in number: |
+1.617.786.2961 |
|
- China Toll Free Number: |
10 800 152 1490 (North) |
|
10 800 852 1490 (South) |
||
- Hong Kong Toll Free Number: |
800 96 3844 |
|
Passcode: |
SHP |
|
A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.
A telephone replay of the call will be available for seven days from August 22, 2011 to August 29, 2011. The dial-in details for the replay are as follows:
- U.S. Toll Free Number: |
1-888-286-8010 |
|
- International dial-in number: |
+1-617-801-6888 |
|
Passcode: |
30402871 |
|
About ShangPharma Corp.
ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.
For further information, please contact: |
|
ShangPharma Corporation |
|
Lan Xie, VP of Finance and Operations |
|
E-mail: [email protected] |
|
Christensen |
|
In New York |
|
Kimberly Minarovich, |
|
Phone: +1 917-533-3268 |
|
E-mail: [email protected] |
|
In Hong Kong |
|
Tip Fleming |
|
Phone: +852-9212-0684 |
|
Email: [email protected] |
|
SOURCE ShangPharma Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article